SRPT Today - Jul 11: Biotech Rout Hits Hard
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
SRPT Today - Jul 11: Biotech Rout Hits Hard
-
ナレーター：
-
著者：
So, what went down? SRPT got smoked today, dropping like a rock after hours. It seems like the whole biotech sector is taking a beating, and Sarepta wasn’t spared. The news hit that there was a setback with one of their DMD drugs, plus their CEO decided to bounce. That combo really rattled investors, and you could see the panic as folks rushed to hit the sell button.
Now, why did this happen? Well, the articles I read pointed out that the drug news was a big deal. DMD, or Duchenne Muscular Dystrophy, is a major focus for Sarepta, so any hiccup there is a big red flag. Plus, with the CEO leaving, it raises questions about the company’s direction. Investors hate uncertainty, and this was a double whammy that sent them running.
And let’s not forget the broader market vibe. Biotech stocks are in a bit of a free fall right now, and Sarepta is part of that mess. Moderna was down a whopping 11%, and it looks like SRPT just got caught up in the chaos. When big players take a hit, it drags others down with them, and that’s exactly what we saw today.
Looking ahead, the analysts are still trying to find the silver lining. Mizuho Securities is sticking with a buy rating and a target price of $31, while Piper Sandler lowered their target to $20. So, there’s some mixed feelings about where this is headed, depending on who you ask.
So, to wrap it up, SRPT had a tough day, caught in a biotech storm with some serious news hitting hard. Just remember, this is all for fun and info – I’m not here to give you financial advice. Stay savvy out there, and catch you later!
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません